Navigation Links
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:10/31/2008

TREANDA Receives Second Indication this Year; Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have Progressed

Following a Rituximab-Containing Regimen

FRAZER, Pa., Oct. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. The data supporting the FDA approval show that TREANDA is effective, has a tolerable side effect profile in patients with indolent NHL and that treatment results in a high durable response rate. In March of this year, TREANDA received approval for the treatment of patients with chronic lymphocytic leukemia, the most common form of leukemia in the United States.

Indolent NHL, a subset of non-Hodgkin's lymphoma, is a slow growing but serious cancer of the lymphatic system that is not curable with currently available treatments. Patients with indolent NHL are prone to multiple relapses after initial therapy. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed this year with indolent NHL.

"Because most patients with indolent non-Hodgkin's lymphoma eventually become resistant to existing treatments, new treatment options like TREANDA are needed to improve patient outcome," stated Dr. Bruce Cheson, Professor of Medicine at Georgetown University Hospital, Washington, D.C. and TREANDA clinical investigator. "The TREANDA pivotal trial shows that it is an effective and well-tolerated chemotherapy that offers a delay in disease progression for more than nine months."

According to Dr. Lesley Russell, Executive Vice President and Chief Medical Officer, Cephalon, "We are excited about this seco
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
2. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
3. Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA
4. Cephalon Conference Call Invitation
5. Cephalon Reports Strong First Quarter Earnings
6. Cephalon Appoints Gerald J. Pappert as General Counsel
7. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
8. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
9. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Physicians in China are most ... treatment of non-Hodgkin’s lymphoma (NHL), according to a new ... healthcare consulting firm. MabThera is the only biologic available ... common form of NHL. , According to Kantar Health’s ... incidence of NHL in China has been growing and ...
(Date:12/22/2014)... December 22, 2014 Give a loved ... the gift of health and vitality. , For a ... three top-selling anti-aging formulas in special Holiday Wellness gift ... delivery. , Each bottle contains cutting-edge, proven nutritional ... don't work as well as we age. ...
(Date:12/22/2014)... 7,178 small business owners and marketing professionals avoided ... opted instead to join Digital Marketer, an Austin, Texas ... annual “Black Friday Boot Camp”. , ... 5 hour online training event and raised $50,000 in ... Central Texas based charities dedicated to fighting childhood cancer. ...
(Date:12/22/2014)... NAPW honors Cheryl ... the Year. She is recognized with this prestigious distinction ... networking organization of professional women in the country, spanning ... Professional Women is a vibrant networking community with over ... Kreider is passionate and committed to best practices that ...
(Date:12/21/2014)... 22, 2014 In this report, ... by power source, product, and application. The market, ... and pneumatic instruments. By product, the market covers ... segments. The handpieces market is further subdivided into ... coagulators, laparoscopic instruments, shavers, wire/pin drivers, and others. ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... on a massive immunization drive aimed at protecting millions of ... nearly 10% of the// children could die in the face ... conducting the MMR (measles, mumps and rubella) immunization campaign which ... by the European Commission. ,The World Health Organization ...
... that there has been a tremendous increase in the number of ... major strain on the already burdened health system. ,According ... climb at the rate of 45% which will overtake the even ... 100,000 in the Asian region. It is the European countries which ...
... in Canada’s hospitals has improved, but targets for some ... released by Wait Time Alliance of the Canadian Medical ... information to patients about exact treatment times, especially for ... keep up the target, which is good news. Nearly ...
... up fast with the third world whether it is infant ... it was reported that Galway, the third largest city in ... taking ill because of water contamination. ,Now the ... that raw sewage has been pouring into the river Forth, ...
... from Canadian experts show that the country will soon become ... Statistics Canada warned// Tuesday that Canada would have to rely ... Canada’s aging workforce puts up their legs. , ... Canada. What distinguishes Canada is the relatively large size of ...
... more than a fad. The technology, which does away with ... to a socket to access// Internet, has spread to half ... schools across the UK. , Meanwhile, there has ... Teachers Union are asking for these wireless network communications to ...
Cached Medicine News:Health News:Cancer Time Bomb Threatening Economic Infrastructure 2Health News:Sewage Swamps River in Scotland 2Health News:Statisticians Alarmed As Canada Zooms Towards Labour Shortage 2Health News:Wire-Free – Handcuffing Good Healt 2
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held ... Moraviec has been appointed Interim Chief Executive Officer of ... Moraviec succeeds Ken Berger .  "The Board of ... in leading ConvaTec over the past three years," said ... of Directors.  "We are confident that the company is ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... SAN DIEGO , Dec. 22, 2014  Pfenex ... Px563L, Pfenex,s recombinant anthrax vaccine, has been filed and ... additional funding provided by the Department of Health and ... Development Authority (BARDA). "We are extremely pleased ... anthrax vaccine, Px563L.  This represents a significant milestone in ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
... Medtronic Ophthalmics offers the most ... specialty Eraser Instruments for Cataract incision, ... and discrete coagulation is achieved with ... cellular necrosis. Straight eraser styles are ...
Medicine Products: